Biogen Appoints Mark Hernon as SVP, Chief Information Officer Dec 4, 2017 07:30AM
Biogen (BIIB) and Alkermes (ALKS) Announce Pact to Develop and Commercialize ALKS 8700 for Treatment of MS Nov 27, 2017 07:02AM
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis Nov 27, 2017 07:00AM
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis Nov 27, 2017 07:00AM
Biogen (BIIB) Names Jeff Capello as EVP and Chief Financial Officer Nov 21, 2017 07:35AM
View Older Stories

Nov 21, 2017 07:30AM Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Nov 2, 2017 04:30PM Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Nov 2, 2017 07:30AM Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Nov 1, 2017 05:07PM Biogen (BIIB), Ionis (IONS) Announces NEJM Publishes First Phase 3 Study Results of SPINRAZA for Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:06PM The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
Oct 27, 2017 07:50AM Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Oct 25, 2017 01:00AM Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Oct 18, 2017 07:30AM Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Oct 10, 2017 07:03AM Align Biopharma Introduces New Technology Standard to Enable Single Sign-on for Healthcare Providers
Oct 5, 2017 07:30AM Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Sep 25, 2017 09:23AM Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Sep 12, 2017 07:30AM Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Aug 28, 2017 07:30AM Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Aug 24, 2017 07:05PM IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
Jul 31, 2017 09:00AM Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Jul 24, 2017 04:15PM Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
Jul 14, 2017 07:32AM Biogen (BIIB) Plans to Present Data at AAIC
Jul 14, 2017 07:30AM Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Jul 10, 2017 07:30AM Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs
Jun 29, 2017 07:33AM Biogen (BIIB) Says New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA in SMA
Jun 29, 2017 07:30AM New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Jun 28, 2017 07:30AM Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Jun 23, 2017 07:57AM Biogen (BIIB) Announces IMRALDI, Biosimilar Candidate Referencing Humira, Granted Positive Opinion by CHMP
Jun 23, 2017 07:55AM Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
Jun 20, 2017 07:30AM Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
Jun 14, 2017 07:30AM Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations
Jun 13, 2017 04:16PM Biogen (BIIB) CFO to Leave to Join Another Biopharmaceutical Company
Jun 13, 2017 04:15PM Biogen Announces Management Change
Jun 1, 2017 07:31AM Biogen (BIIB) Says SPINRAZA Approved in EU as First Treatment for Spinal Muscular Atrophy
Jun 1, 2017 07:30AM SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
May 24, 2017 01:30AM Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
May 17, 2017 04:01PM Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
May 15, 2017 07:31AM Biogen (BIIB) to Acquire Remedy Pharmaceuticals' Phase 3 Candidate CIRARA for Large Hemispheric Stroke
May 15, 2017 07:30AM Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
Apr 24, 2017 07:39AM Biogen (BIIB) Says TECFIDERA and TYSABRI Data Shows Improved Outcomes with Early MS Treatment
Apr 24, 2017 07:32AM Biogen (BIIB) Says Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset SMA
Apr 24, 2017 07:30AM TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
Apr 24, 2017 07:30AM Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Apr 21, 2017 02:00PM Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Apr 18, 2017 07:33AM Biogen (BIIB) to Present Data on Neurology Research Programs and Portfolio at AAN
Apr 18, 2017 07:30AM Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
Apr 13, 2017 07:10AM Biogen (BIIB) Confirms Agreement to License Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb (BMY)
Apr 13, 2017 07:00AM Bristol-Myers Squibb (BMY) Enters Agreements to License Anti-eTau, Anti-Myostatin Compounds to Biogen (BIIB), Roche
Apr 13, 2017 07:00AM Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
Apr 13, 2017 06:59AM Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively
Mar 28, 2017 07:31AM Biogen (BIIB) to Present Alzheimer's and Parkinson's Data at AD/PD
Mar 28, 2017 07:30AM Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
Mar 16, 2017 07:00AM Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development
Jan 17, 2017 10:30AM Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
Jan 13, 2017 07:33AM Biogen (BIIB) Phase 3 Data on SPINRAZA Shows Significantly Reduced Risk of Death in SMA
View Older Stories